Article(id=1329913682013827804, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329913625835319315, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2018.12.013, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1533657600000, receivedDateStr=2018-08-08, revisedDate=1536508800000, revisedDateStr=2018-09-10, acceptedDate=null, acceptedDateStr=null, onlineDate=1795005730392, onlineDateStr=2026-11-18, pubDate=1544371200000, pubDateStr=2018-12-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795005730392, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795005730392, creator=13701087609, updateTime=1795005730392, updator=13701087609, issue=Issue{id=1329913625835319315, tenantId=1146029695717560320, journalId=1319690329412173987, year='2018', volume='39', issue='12', pageStart='793', pageEnd='864', issueExtLink='null', onlineDate='null', pubDate='1544371200000', pubDateStr='2018-12-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795005716998, creator='13701087609', updateTime=1795056425343, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330126312536126326, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329913625835319315, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330126312536126327, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329913625835319315, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=856, endPage=863, ext={EN=ArticleExt(id=1329913682194182877, articleId=1329913682013827804, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of human glucagon-like peptide-1 receptor agonist semaglutide, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=

Semaglutide is a long-acting human glucagon-like peptide-1 (GLP-1) receptor agonist, which can be used to assist in diet control and exercise to improve blood glucose in type 2 diabetes mellitus patients. This drug is available to be formulated as both subcutaneous and oral dosage form. Subcutaneous dosage forms are currently approved by FDA, and the oral dosage forms is still in the clinical phase Ⅲ stage. This article describes the mechanism, pharmacology, pharmacokinetics and clinical research progress of semaglutide.

, authors=Jiang-xiong RUAN, Li-ping XIE, You-jia HU*, authorsList=Jiang-xiong RUAN, Li-ping XIE, You-jia HU, authorCompany=null, correspAuthors=You-jia HU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329913682408092382, articleId=1329913682013827804, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=人胰高血糖素样肽-1受体激动剂索马鲁肽的研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

索马鲁肽是一种长效的人胰高血糖素样肽-1(GLP-1)受体激动剂,用于辅助饮食控制和运动以改善2型糖尿病患者的血糖。该药有皮下注射和口服两种剂型,皮下注射剂型目前已获美国食品药品管理局批准,口服剂型尚处于临床Ⅲ期开发阶段。本文通过文献检索,综述索马鲁肽作用机制、药理学、药动学和临床研究进展。

, authors=阮江雄, 谢丽萍, 胡又佳*, authorsList=阮江雄, 谢丽萍, 胡又佳, authorCompany=null, correspAuthors=胡又佳, authorNote=

阮江雄,硕士研究生,研究方向:生物制药。

, correspAuthorsNote=
胡又佳,研究员,研究方向:生物制药。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=fGNXWwiLtaTI9lzTmDX2CQ==, magXml=L9yAZ6mI5n6jj+ZrDw393w==, pdfUrl=null, pdf=ztGn2FG45V+BjUOel9iXgw==, pdfFileSize=1087766, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=WsBnwMLgTN0ZUbiJo3296A==, mapNumber=null, fund=null)}, authors=[Author(id=1329913682705887971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329913682781385445, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682705887971, language=EN, stringName=Jiang-xiong RUAN, firstName=Jiang-xiong, middleName=null, lastName=RUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913682848494310, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682705887971, language=CN, stringName=阮江雄, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院张江分院,上海 201203, bio={"content":"

阮江雄,硕士研究生,研究方向:生物制药。

"}, bioImg=null, bioContent=

阮江雄,硕士研究生,研究方向:生物制药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])]), Author(id=1329913682911408872, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329913682986906346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682911408872, language=EN, stringName=Li-ping XIE, firstName=Li-ping, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913683049820907, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682911408872, language=CN, stringName=谢丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院张江分院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])]), Author(id=1329913683121124077, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329913683192427247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913683121124077, language=EN, stringName=You-jia HU, firstName=You-jia, middleName=null, lastName=HU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913683267924720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913683121124077, language=CN, stringName=胡又佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院张江分院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])])], keywords=[Keyword(id=1329913683372782321, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=EN, orderNo=1, keyword=semaglutide), Keyword(id=1329913683435696882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=EN, orderNo=2, keyword=human glucagon-like peptide-1 receptor agonist), Keyword(id=1329913683502805747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=EN, orderNo=3, keyword=clinical research), Keyword(id=1329913683578303220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=EN, orderNo=4, keyword=type 2 diabetes mellitus), Keyword(id=1329913683649606389, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=CN, orderNo=1, keyword=索马鲁肽), Keyword(id=1329913683708326646, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=CN, orderNo=2, keyword=人胰高血糖素样肽-1受体激动剂), Keyword(id=1329913683796407031, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=CN, orderNo=3, keyword=临床研究), Keyword(id=1329913683859321592, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, language=CN, orderNo=4, keyword=2型糖尿病)], refs=[Reference(id=1329913683955790585, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic[J]. Nature, 2001, 414(6865): 782-787., articleTitle=null, refAbstract=null), Reference(id=1329913684018705146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet, 2011, 378(9785): 31-40., articleTitle=null, refAbstract=null), Reference(id=1329913684081619707, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138: 271-271., articleTitle=null, refAbstract=null), Reference(id=1329913684144534268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Kumar N, Mishra SS, Sharma CS, et al. Potential of semaglutide in the treatment of type 2 diabetes mellitus: an overview[J]. Int J Pharm Technol Bio, 2015, 2(4): 23-35., articleTitle=null, refAbstract=null), Reference(id=1329913684207448829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research[J]. Diabetes Metab Syndr Obes, 2017, 10: 123-139., articleTitle=null, refAbstract=null), Reference(id=1329913684282946302, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2012, 8(12): 728-742., articleTitle=null, refAbstract=null), Reference(id=1329913684350055167, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus[J]. Am J Health syst Pharm, 2005, 62(2): 173-181., articleTitle=null, refAbstract=null), Reference(id=1329913684421358336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)[J]. Lancet, 2009, 374(9683): 39-47., articleTitle=null, refAbstract=null), Reference(id=1329913684488467201, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men[J]. Diabetologia, 2002, 45(2): 195-202., articleTitle=null, refAbstract=null), Reference(id=1329913684547187458, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide[J]. J Med Chem, 2015, 58(18): 7370-7380., articleTitle=null, refAbstract=null), Reference(id=1329913684610102019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Kalra S. Choosing appropriate glucagon-like peptide 1 receptor agonists: a patient-centered approach[J]. Diabetes Ther, 2014, 5(1): 333-340., articleTitle=null, refAbstract=null), Reference(id=1329913684681405188, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Marre M, Penfornis A. GLP-1 receptor agonists today[J]. Diabetes Res Clin Pract, 2011, 93(3): 317-327., articleTitle=null, refAbstract=null), Reference(id=1329913684752708357, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Nauck MA, Petrie JR, Sesti G, et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbAlc and body weight in patients with type 2 diabetes[J]. Diabetologia, 2012, 55(Suppl 1): S7-S7., articleTitle=null, refAbstract=null), Reference(id=1329913684819817222, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Gotfredsen CF, Molck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates[J]. Diabetes, 2014, 63(7): 2486-2497., articleTitle=null, refAbstract=null), Reference(id=1329913684886926087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaspar AA, Reichert JM. Future directions for peptide therapeutics development[J]. Drug Discov Today, 2013, 18(17-18): 807-817., articleTitle=null, refAbstract=null), Reference(id=1329913684975006472, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species[J]. Eur J Pharm Sci, 2017, 104: 31-41., articleTitle=null, refAbstract=null), Reference(id=1329913685046309641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists[J]. Cardiovasc Diabetol, 2014, 13(1): 142-142., articleTitle=null, refAbstract=null), Reference(id=1329913685113418506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Fujiwara S, Amisaki T. Fatty acid binding to serum albumin: molecular simulation approaches[J]. Biochim Biophys Acta, 2013, 1830(12): 5427-5434., articleTitle=null, refAbstract=null), Reference(id=1329913685188915979, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel[J]. J Clin Pharmacol, 2015, 55(5): 497-504., articleTitle=null, refAbstract=null), Reference(id=1329913685260219148, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Novo nordisk. Ozempic assessment report[EB/OL]. [2018-07-10]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004174/WC500244165.pdf., articleTitle=null, refAbstract=null), Reference(id=1329913685327328013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Lund A, Knop FK, Vilsboll T. Glucagon like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities[J]. Eur J Intern Med, 2014, 25(5): 407-414., articleTitle=null, refAbstract=null), Reference(id=1329913685390242574, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Tibble CA, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature[J]. Exp Rev Endocrinol Metab, 2014, 8(3): 247-259., articleTitle=null, refAbstract=null), Reference(id=1329913685461545743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity[J]. Bioorg Med Chem Lett, 2013, 23(14): 4011-4018., articleTitle=null, refAbstract=null), Reference(id=1329913685524460304, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes[J]. Diabetes Care, 2016, 39(2): 231-241., articleTitle=null, refAbstract=null), Reference(id=1329913685604152081, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Eng J Med, 2016, 375(19): 1834-1844., articleTitle=null, refAbstract=null), Reference(id=1329913685688038162, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Kapitza C, Lynge J, Düring M, et al. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects[J]. Diabetologia, 2012, 55(Suppl 1): S341-S341., articleTitle=null, refAbstract=null), Reference(id=1329913685759341331, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment[J]. Hosp Pract, 2012, 40(2): 7-21., articleTitle=null, refAbstract=null), Reference(id=1329913685826450196, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature[J]. Endocrine, 2014, 46(3): 406-419., articleTitle=null, refAbstract=null), Reference(id=1329913685897753365, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Young MA, Wald JA, Matthews JE, et al. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide[J]. Postgrad Med, 2014, 126(3): 35-46., articleTitle=null, refAbstract=null), Reference(id=1329913685956473622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide[J]. Br J Clin Pharmacol, 2009, 68(6): 898-905., articleTitle=null, refAbstract=null), Reference(id=1329913686019388183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Hermansen K, Kolotkin RL, Hammer M, et al. Patient reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin[J]. Prim Care Diabetes, 2010, 4(2): 113-117., articleTitle=null, refAbstract=null), Reference(id=1329913686082302744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Mikhail NE. Is liraglutide a useful addition to diabetes therapy?[J]. Endocr Pract, 2010, 16(6): 1028-1037., articleTitle=null, refAbstract=null), Reference(id=1329913686149411609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide[J]. Br J Clin Pharmacol, 2007, 64(3): 317-327., articleTitle=null, refAbstract=null), Reference(id=1329913686254269210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial[J]. Diabetes Care, 2016, 39(2): 222-230., articleTitle=null, refAbstract=null), Reference(id=1329913686325572379, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Melanie D, Sudesna C, Kamlesh K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies[J]. Clin Pharmacol, 2016, 8: 61-81., articleTitle=null, refAbstract=null), Reference(id=1329913686396875548, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment[J]. Clin Pharmacokinet, 2017, 56(11): 1381-1390., articleTitle=null, refAbstract=null), Reference(id=1329913686472373021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Jensen L, Kupcova V, Arold G, et al. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment[J]. Diabetes Obes Metab, 2018, 20(4): 998-1005., articleTitle=null, refAbstract=null), Reference(id=1329913686547870494, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus[J]. Diabetes Metab, 2013, 39(6): 485-496., articleTitle=null, refAbstract=null), Reference(id=1329913686631756575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicenter phase 3a trial[J]. Lancet Diabetes Endocrinol, 2017, 5(4): 251-260., articleTitle=null, refAbstract=null), Reference(id=1329913686698865440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an addonto metformin, thiazolidinediones, or both, in patients with type2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial[J]. Lancet Diabetes Endocrinol, 2017, 5(5): 341-354., articleTitle=null, refAbstract=null), Reference(id=1329913686761780001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial[J]. Diabetes Care, 2018, 41(2): 258-266., articleTitle=null, refAbstract=null), Reference(id=1329913686841471778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Liutkus J, Aroda VR, Bain SC, et al. Efficacy and safety of once-weekly semaglutide vs. once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)[J]. Can J Diabetes, 2016, 40(5): S41-S41., articleTitle=null, refAbstract=null), Reference(id=1329913686908580643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Conway R, Rodbard H, Lingvay I, et al. Efficacy and safety of semaglutide once-weekly vs. placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5)[J]. Can J Diabetes, 2016, 40(5): S41-S42., articleTitle=null, refAbstract=null), Reference(id=1329913686979883812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Leiter L, Jodar E, Damgaard L, et al. SUSTAIN 6: a posthoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes[J]. Can J Cardiology, 2017, 33(10): S28-S29., articleTitle=null, refAbstract=null), Reference(id=1329913687055381285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Eng J Med, 2016, 375(19): 1834-1844., articleTitle=null, refAbstract=null), Reference(id=1329913687143461670, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial[J]. Lancet Diabetes Endocrinol, 2018, 6(4): 275-286., articleTitle=null, refAbstract=null), Reference(id=1329913687214764840, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Davies M, Pieber TR, Hartoftnielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial[J]. J Am Med Assoc, 2017, 318(15): 1460-1470., articleTitle=null, refAbstract=null), Reference(id=1329913687281873705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Novo Nordisk. Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial[EB/OL]. [2018-07-10]. https://www.novonordisk.com/media/news-details.2200856.html., articleTitle=null, refAbstract=null), Reference(id=1329913687344788266, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Novo Nordisk. Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial[EB/OL]. [2018-07-10]. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2195846.html., articleTitle=null, refAbstract=null), Reference(id=1329913687407702827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Novo Nordisk. Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza and sitagliptin in the PIONEER 4 and 7 trials[EB/OL]. [2018-07-10]. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2200408.html., articleTitle=null, refAbstract=null), Reference(id=1329913687483200300, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Dhillon S. Semaglutide: first global approval[J]. Drugs, 2018, 78(2): 275-284., articleTitle=null, refAbstract=null), Reference(id=1329913687537726253, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneoususe: US prescribinginformation[EB/OL]. [2018-07-10]. http://www.novopi.com/ozempic.pdf.www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1329913687604835118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy[J]. Diabetes Obesity Metabolism, 2018, 20(4): 889-897., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.12.013, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2018.12.013, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2018.12.013, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2018.12.013, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1544371200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
人胰高血糖素样肽-1受体激动剂索马鲁肽的研究进展
阮江雄 , 谢丽萍 , 胡又佳 *
世界临床药物 | 综述评论 2018,39(12): 856-863
收起
收藏切换
世界临床药物 |综述评论 2018 , 39 (12) : 856 -863
人胰高血糖素样肽-1受体激动剂索马鲁肽的研究进展
全屏
[Author(id=1329913682705887971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329913682781385445, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682705887971, language=EN, stringName=Jiang-xiong RUAN, firstName=Jiang-xiong, middleName=null, lastName=RUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913682848494310, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682705887971, language=CN, stringName=阮江雄, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院张江分院,上海 201203, bio={"content":"

阮江雄,硕士研究生,研究方向:生物制药。

"}, bioImg=null, bioContent=

阮江雄,硕士研究生,研究方向:生物制药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])]), Author(id=1329913682911408872, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329913682986906346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682911408872, language=EN, stringName=Li-ping XIE, firstName=Li-ping, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913683049820907, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913682911408872, language=CN, stringName=谢丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院张江分院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])]), Author(id=1329913683121124077, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329913683192427247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913683121124077, language=EN, stringName=You-jia HU, firstName=You-jia, middleName=null, lastName=HU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913683267924720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, authorId=1329913683121124077, language=CN, stringName=胡又佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院张江分院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913682609418975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, xref=null, ext=[AuthorCompanyExt(id=1329913682622001888, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329913682638779105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913682013827804, companyId=1329913682609418975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院张江分院,上海 201203)])])]
阮江雄, 谢丽萍, 胡又佳*
作者信息
  • 中国医药工业研究总院张江分院,上海 201203
通讯作者:
胡又佳,研究员,研究方向:生物制药。
作者简介:

阮江雄,硕士研究生,研究方向:生物制药。

Research progress of human glucagon-like peptide-1 receptor agonist semaglutide
Jiang-xiong RUAN, Li-ping XIE, You-jia HU*
Affiliations
  • Zhangjiang Institute, China State Institute of Pharmaceutical Industry, Shanghai 201203, China
出版时间: 2018-12-10 doi: 10.13683/j.wph.2018.12.013
文章导航
收藏切换

索马鲁肽是一种长效的人胰高血糖素样肽-1(GLP-1)受体激动剂,用于辅助饮食控制和运动以改善2型糖尿病患者的血糖。该药有皮下注射和口服两种剂型,皮下注射剂型目前已获美国食品药品管理局批准,口服剂型尚处于临床Ⅲ期开发阶段。本文通过文献检索,综述索马鲁肽作用机制、药理学、药动学和临床研究进展。

索马鲁肽  /  人胰高血糖素样肽-1受体激动剂  /  临床研究  /  2型糖尿病

Semaglutide is a long-acting human glucagon-like peptide-1 (GLP-1) receptor agonist, which can be used to assist in diet control and exercise to improve blood glucose in type 2 diabetes mellitus patients. This drug is available to be formulated as both subcutaneous and oral dosage form. Subcutaneous dosage forms are currently approved by FDA, and the oral dosage forms is still in the clinical phase Ⅲ stage. This article describes the mechanism, pharmacology, pharmacokinetics and clinical research progress of semaglutide.

semaglutide  /  human glucagon-like peptide-1 receptor agonist  /  clinical research  /  type 2 diabetes mellitus
阮江雄, 谢丽萍, 胡又佳. 人胰高血糖素样肽-1受体激动剂索马鲁肽的研究进展. 世界临床药物, 2018 , 39 (12) : 856 -863 . DOI: 10.13683/j.wph.2018.12.013
Jiang-xiong RUAN, Li-ping XIE, You-jia HU. Research progress of human glucagon-like peptide-1 receptor agonist semaglutide[J]. World Clinical Drug, 2018 , 39 (12) : 856 -863 . DOI: 10.13683/j.wph.2018.12.013

参考文献 引证文献
排序方式:
[1]
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic[J]. Nature, 2001, 414(6865): 782-787.
[2]
Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet, 2011, 378(9785): 31-40.
[3]
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138: 271-271.
[4]
Kumar N, Mishra SS, Sharma CS, et al. Potential of semaglutide in the treatment of type 2 diabetes mellitus: an overview[J]. Int J Pharm Technol Bio, 2015, 2(4): 23-35.
[5]
Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research[J]. Diabetes Metab Syndr Obes, 2017, 10: 123-139.
[6]
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2012, 8(12): 728-742.
[7]
Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus[J]. Am J Health syst Pharm, 2005, 62(2): 173-181.
[8]
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)[J]. Lancet, 2009, 374(9683): 39-47.
[9]
Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men[J]. Diabetologia, 2002, 45(2): 195-202.
[10]
Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide[J]. J Med Chem, 2015, 58(18): 7370-7380.
[11]
Kalra S. Choosing appropriate glucagon-like peptide 1 receptor agonists: a patient-centered approach[J]. Diabetes Ther, 2014, 5(1): 333-340.
[12]
Marre M, Penfornis A. GLP-1 receptor agonists today[J]. Diabetes Res Clin Pract, 2011, 93(3): 317-327.
[13]
Nauck MA, Petrie JR, Sesti G, et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbAlc and body weight in patients with type 2 diabetes[J]. Diabetologia, 2012, 55(Suppl 1): S7-S7.
[14]
Gotfredsen CF, Molck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates[J]. Diabetes, 2014, 63(7): 2486-2497.
[15]
Kaspar AA, Reichert JM. Future directions for peptide therapeutics development[J]. Drug Discov Today, 2013, 18(17-18): 807-817.
[16]
Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species[J]. Eur J Pharm Sci, 2017, 104: 31-41.
[17]
Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists[J]. Cardiovasc Diabetol, 2014, 13(1): 142-142.
[18]
Fujiwara S, Amisaki T. Fatty acid binding to serum albumin: molecular simulation approaches[J]. Biochim Biophys Acta, 2013, 1830(12): 5427-5434.
[19]
Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel[J]. J Clin Pharmacol, 2015, 55(5): 497-504.
[20]
Novo nordisk. Ozempic assessment report[EB/OL]. [2018-07-10]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004174/WC500244165.pdf.
[21]
Lund A, Knop FK, Vilsboll T. Glucagon like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities[J]. Eur J Intern Med, 2014, 25(5): 407-414.
[22]
Tibble CA, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature[J]. Exp Rev Endocrinol Metab, 2014, 8(3): 247-259.
[23]
Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity[J]. Bioorg Med Chem Lett, 2013, 23(14): 4011-4018.
[24]
Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes[J]. Diabetes Care, 2016, 39(2): 231-241.
[25]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Eng J Med, 2016, 375(19): 1834-1844.
[26]
Kapitza C, Lynge J, Düring M, et al. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects[J]. Diabetologia, 2012, 55(Suppl 1): S341-S341.
[27]
Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment[J]. Hosp Pract, 2012, 40(2): 7-21.
[28]
Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature[J]. Endocrine, 2014, 46(3): 406-419.
[29]
Young MA, Wald JA, Matthews JE, et al. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide[J]. Postgrad Med, 2014, 126(3): 35-46.
[30]
Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide[J]. Br J Clin Pharmacol, 2009, 68(6): 898-905.
[31]
Hermansen K, Kolotkin RL, Hammer M, et al. Patient reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin[J]. Prim Care Diabetes, 2010, 4(2): 113-117.
[32]
Mikhail NE. Is liraglutide a useful addition to diabetes therapy?[J]. Endocr Pract, 2010, 16(6): 1028-1037.
[33]
Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide[J]. Br J Clin Pharmacol, 2007, 64(3): 317-327.
[34]
Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial[J]. Diabetes Care, 2016, 39(2): 222-230.
[35]
Melanie D, Sudesna C, Kamlesh K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies[J]. Clin Pharmacol, 2016, 8: 61-81.
[36]
Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment[J]. Clin Pharmacokinet, 2017, 56(11): 1381-1390.
[37]
Jensen L, Kupcova V, Arold G, et al. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment[J]. Diabetes Obes Metab, 2018, 20(4): 998-1005.
[38]
Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus[J]. Diabetes Metab, 2013, 39(6): 485-496.
[39]
Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicenter phase 3a trial[J]. Lancet Diabetes Endocrinol, 2017, 5(4): 251-260.
[40]
Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an addonto metformin, thiazolidinediones, or both, in patients with type2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial[J]. Lancet Diabetes Endocrinol, 2017, 5(5): 341-354.
[41]
Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial[J]. Diabetes Care, 2018, 41(2): 258-266.
[42]
Liutkus J, Aroda VR, Bain SC, et al. Efficacy and safety of once-weekly semaglutide vs. once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)[J]. Can J Diabetes, 2016, 40(5): S41-S41.
[43]
Conway R, Rodbard H, Lingvay I, et al. Efficacy and safety of semaglutide once-weekly vs. placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5)[J]. Can J Diabetes, 2016, 40(5): S41-S42.
[44]
Leiter L, Jodar E, Damgaard L, et al. SUSTAIN 6: a posthoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes[J]. Can J Cardiology, 2017, 33(10): S28-S29.
[45]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Eng J Med, 2016, 375(19): 1834-1844.
[46]
Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial[J]. Lancet Diabetes Endocrinol, 2018, 6(4): 275-286.
[47]
Davies M, Pieber TR, Hartoftnielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial[J]. J Am Med Assoc, 2017, 318(15): 1460-1470.
[48]
Novo Nordisk. Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial[EB/OL]. [2018-07-10]. https://www.novonordisk.com/media/news-details.2200856.html.
[49]
Novo Nordisk. Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial[EB/OL]. [2018-07-10]. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2195846.html.
[50]
Novo Nordisk. Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza and sitagliptin in the PIONEER 4 and 7 trials[EB/OL]. [2018-07-10]. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2200408.html.
[51]
Dhillon S. Semaglutide: first global approval[J]. Drugs, 2018, 78(2): 275-284.
[52]
Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneoususe: US prescribinginformation[EB/OL]. [2018-07-10]. http://www.novopi.com/ozempic.pdf.www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf.
[53]
Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy[J]. Diabetes Obesity Metabolism, 2018, 20(4): 889-897.
2018年第39卷第12期
17
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2018.12.013
  • 接收时间:2018-08-08
  • 首发时间:2026-11-18
  • 出版时间:2018-12-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2018-08-08
  • 修回日期:2018-09-10
基金
作者信息
    中国医药工业研究总院张江分院,上海 201203

通讯作者:

胡又佳,研究员,研究方向:生物制药。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.12.013
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏